Advertisement
UK markets closed
  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     
  • FTSE 250

    20,120.36
    -75.59 (-0.37%)
     
  • AIM

    776.04
    -4.39 (-0.56%)
     
  • GBP/EUR

    1.1845
    -0.0034 (-0.29%)
     
  • GBP/USD

    1.2686
    -0.0075 (-0.59%)
     
  • Bitcoin GBP

    52,285.03
    +587.11 (+1.14%)
     
  • CMC Crypto 200

    1,406.00
    -11.88 (-0.84%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     
  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     

Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

Fate Therapeutics (NASDAQ:FATE) First Quarter 2024 Results

Key Financial Results

  • Net loss: US$48.0m (loss widened by 154% from 1Q 2023).

  • US$0.47 loss per share (further deteriorated from US$0.19 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fate Therapeutics Revenues Beat Expectations

Revenue exceeded analyst estimates by 53%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

ADVERTISEMENT

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Fate Therapeutics is showing 4 warning signs in our investment analysis and 1 of those shouldn't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.